Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 February 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Noninvasive markers of liver fibrosis in drug users with Hep C

FibroSURE, alanine aminotransferase, and aminotransferase-to-platelet-ratio index tests predict insignificant fibrosis in injection drug users with Hep C, reports this month's Hepatology.

News image

fiogf49gjkf04

Most Hepatitis C virus infections are acquired by injection drug use.

Dr Lucy Wilson and colleagues from the USA assessed prospective data on the progression of liver fibrosis.

Baseline liver biopsies were obtained from 1996 to 1998 on a random sample of 210 out of 1667 Hepatitis C virus-positive injection drug users.

Subjects were followed biannually, with a second biopsy offered to those eligible.

Among 119 prospectively followed injection drug users, 96% were African American, and 97% were Hepatitis C virus genotype 1a/b.

A further 27% were HIV-infected, with a median age of 42 years.

Paired biopsies were scored from 0 to 6.

The research team defined significant fibrosis was as score 3 or greater.

Progression of fibrosis was defined as an increase 2 or more units or clinical evidence of end-stage liver disease.

The predictive value for alanine aminotransferase specificities was 73%
Hepatology

The team's predictive values of blood markers include FibroSURE, aspartate aminotransferase-to-platelet-ratio index and alanine aminotransferase.

The researchers assessed the detection of contemporaneous and future liver fibrosis.

The team noted that 91% did not have significant liver fibrosis at first biopsy.

The researchers' predictive value for detecting insignificant fibrosis at first biopsy was greater than 95% for FibroSURE.

The predictive value for aminotransferase-to-platelet-ratio index, and alanine aminotransferase specificities were 73%.

After 4 years median follow-up, 21% had progression of fibrosis.

The researchers observed that this was significantly associated with serum level of Hepatitis C virus RNA and alanine aminotransferase.

No serological test had a predictive value greater than 40% for contemporaneous or future significant fibrosis.

Initial biopsy result had only a 30% value for predicting future significant fibrosis.

Dr Wilson's team concluded, “Significant liver fibrosis and progression were detected in some, but not most, injection drug users in this cohort.”

“In this setting with low fibrosis prevalence, FibroSURE, alanine aminotransferase, and aminotransferase-to-platelet-ratio index tests predict insignificant fibrosis.”

“However, further work is needed to find noninvasive markers of significant liver fibrosis.”

Hepatol 2006: 43(4): 788-95
05 April 2006

Go to top of page Email this page Email this page to a colleague

 17 February 2017 
Genetic mutations predict esophageal cancer
 17 February 2017 
Anesthesia services during outpatient gastroenterology procedures
 17 February 2017 
Genetic mutations predict esophageal cancer
 16 February 2017 
Hysterectomy and pelvic floor disorders
 16 February 2017 
Anesthetist-directed sedation in endoscopic procedures
 16 February 2017 
Assisted reproduction in women with IBD 
 15 February 2017 
Metal stents for palliation in malignant biliary obstruction
 15 February 2017 
Hepatocellular carcinoma in the USA
 15 February 2017 
Increasing screening of cirrhosis in hepatocellular carcinoma
 14 February 2017 
Pathologists agreement in the diagnosis of Barrett's
 14 February 2017 
Preventive care in IBD 
 14 February 2017 
Infliximab dose for acute severe ulcerative colitis
 13 February 2017 
Vasoactive drugs for hepatorenal syndrome type 1
 13 February 2017 
Pregnancy outcomes after endoscopy
 13 February 2017 
H. pylori treatment guidelines
 10 February 2017 
Primary ileocecal resection in pediatric Crohn's disease
 10 February 2017 
Non-adherence in end-stage liver disease
 10 February 2017 
Isolated colonic Crohn's disease
 09 February 2017 
Mucosal healing in ulcerative colitis
 09 February 2017 
NAFLD and coronary artery calcium score
 09 February 2017 
Prevalence of Hep D in chronic Hep B infection
 08 February 2017 
Rifaximin for small intestine bacterial overgrowth
 08 February 2017 
Risk prediction of interval cancers from inadequate colonoscopy quality
 08 February 2017 
Meta-analyses in gastroenterology and hepatology journals
 07 February 2017 
Chemoprevention in colon cancer
 07 February 2017 
Methotrexate intolerance in pediatric IBD 
 07 February 2017 
Untreated hepatocellular carcinoma in the USA
 06 February 2017 
Vitamin D levels and risk of relapse in ulcerative colitis
 06 February 2017 
Giardia in the USA
 06 February 2017 
Colorectal cancer risk in serrated polyposis syndrome
 03 February 2017 
Helicobacter and Campylobacter in IBD
 03 February 2017 
Mortality risk in elderly-onset IBD
 03 February 2017 
Management of chronic refractory pouchitis
 02 February 2017 
IBD-related research and publications
 02 February 2017 
TWEAK in IBD
 02 February 2017 
Clostridium difficile and colectomy risk in IBD
 01 February 2017 
Suboptimal bowel preparation in outpatient colonoscopy
 01 February 2017 
Fecal microbiota transplantation
 01 February 2017 
Socio-economic distribution of IBD 
 31 January 2017 
Gastroenterology fellowship
 31 January 2017 
Approach to Lynch syndrome
 31 January 2017 
Fat intake and ulcerative colitis risk
 30 January 2017 
Dietary risk of acute pancreatitis
 30 January 2017 
Care pathway for anemia in IBD 
 30 January 2017 
Mortality in elderly-onset IBD
 27 January 2017 
Cancer mortality in the USA
 27 January 2017 
Therapeutic drug monitoring in IBD 
 27 January 2017 
Monoclonal antibodies for recurrent C. diff
 26 January 2017 
Propofol for gastrointestinal endoscopy
 26 January 2017 
Therapy in pediatric IBD
 26 January 2017 
Disease knowledge in adolescents with IBD
 24 January 2017 
Course of achalasia
 24 January 2017 
H. pylori and iron deficiency anemia
 24 January 2017 
Hospital transfer and colorectal surgery
 23 January 2017 
Diagnosis of pancreatic cancer
 23 January 2017 
Care pathway for anemia in IBD 
 23 January 2017 
Fatigue in IBD after diagnosis
 20 January 2017 
Predictors of small bowel Crohn's in capsule endoscopy
 20 January 2017 
Stool output after a meal
 20 January 2017 
Abnormalities in functional dyspepsia

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us